Clinical Scorecard: Plerixafor Outperforms Standard Chemotherapy in Initial Stem Cell Mobilization and Remains Effective in Heavily Pretreated Patients

At a Glance

Key Highlights

• Plerixafor combined with G-CSF achieves higher CD34+ stem cell yields in fewer apheresis sessions compared to G-CSF alone or chemotherapy+G-CSF.
• Plerixafor+G-CSF mobilization is less toxic and avoids chemotherapy-associated neutropenia and nausea.
• Clinical outcomes including engraftment time, graft durability, relapse rate, and overall survival are comparable between plerixafor+G-CSF and chemotherapy-based mobilization.

Guideline-Based Recommendations

Diagnosis

• Confirm eligibility for autologous stem cell transplantation in lymphoma or myeloma patients.
• Exclude patients with plasma cell leukemia, myeloid malignancy, acute lymphoblastic leukemia, solid tumors, or prior harvesting attempts for current transplant.

Management

• Use plerixafor (240 μg/kg or 160 μg/kg if creatinine clearance 30–49 ml/min) plus G-CSF (10 μg/kg/day) as first-line mobilization.
• Administer G-CSF for 5–8 days; start plerixafor on day 4 at 22 h for up to 4 doses.
• Perform stem cell harvesting starting day 5 daily until target of ≥4 × 10^6 CD34+ cells/kg or up to 4 aphereses.

Monitoring & Follow-up

• Monitor neutrophil counts to ensure they do not fall below 1.0 × 10^9/L during the 3 weeks post-mobilization initiation.
• Assess CD34+ cell yield after each apheresis session to determine adequacy of collection.

Risks

• Avoid plerixafor in patients with creatinine clearance <30 ml/min.
• Be aware of potential chemotherapy-related toxicities such as neutropenia and nausea when using chemotherapy-based mobilization.

Patient & Prescribing Data

Adults with lymphoma or multiple myeloma undergoing first-line stem cell mobilization for autologous transplantation

Plerixafor+G-CSF mobilization results in higher stem cell yields, fewer apheresis sessions, and lower toxicity compared to chemotherapy+G-CSF, with no compromise in transplantation outcomes.

Clinical Best Practices

• Prefer plerixafor+G-CSF over chemotherapy+G-CSF for first-line stem cell mobilization in eligible lymphoma and myeloma patients.
• Adjust plerixafor dosing based on renal function to optimize safety and efficacy.
• Initiate harvesting promptly after mobilization to maximize stem cell yield and minimize patient burden.
• Use plerixafor+G-CSF as a salvage strategy in patients who fail to mobilize adequately with chemotherapy or G-CSF alone.

References

• ClinicalTrials.gov NCT01186224
• DiPersio et al. Phase III Study of Plerixafor plus G-CSF in Non-Hodgkin Lymphoma
• DiPersio et al. Phase III Study of Plerixafor plus G-CSF in Multiple Myeloma